New cases come from SEER 12. Deaths come from U.S. Mortality. All Races, Both Sexes. Rates are Age-Adjusted. Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software. The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Age-Adjusted Rates of New Cases/Deaths Per 100,000 & 5-Year Relative Survival Percentages
Year
Rate of New Cases — SEER 8
Rate of New Cases — SEER 12
Death Rate — U.S.
5-Year Relative Survival — SEER 8
Observed
Modeled Trend
Observed
Modeled Trend
Observed
Modeled Trend
Observed
Modeled Trend
1975
11.03
10.78
-
-
5.63
5.50
46.68%
50.53%
1976
11.46
11.17
-
-
5.71
5.64
48.21%
50.63%
1977
11.38
11.57
-
-
5.77
5.77
45.24%
50.74%
1978
11.59
11.99
-
-
5.93
5.92
48.12%
50.85%
1979
12.71
12.42
-
-
5.95
6.06
47.87%
50.95%
1980
12.58
12.87
-
-
6.23
6.21
49.05%
51.06%
1981
13.78
13.34
-
-
6.16
6.36
50.87%
51.17%
1982
13.11
13.82
-
-
6.55
6.52
50.64%
51.27%
1983
13.81
14.32
-
-
6.66
6.68
52.57%
51.38%
1984
15.12
14.84
-
-
6.76
6.84
52.48%
51.48%
1985
15.40
15.37
-
-
7.06
7.01
53.12%
51.59%
1986
16.12
15.93
-
-
7.31
7.19
51.42%
51.69%
1987
16.79
16.51
-
-
7.26
7.36
52.64%
51.80%
1988
17.36
17.10
-
-
7.52
7.54
50.85%
51.91%
1989
17.49
17.72
-
-
7.83
7.73
49.90%
52.01%
1990
18.55
18.36
-
-
7.87
7.92
50.17%
52.12%
1991
18.68
19.03
-
-
8.19
8.11
51.01%
52.22%
1992
18.89
19.14
18.70
19.02
8.22
8.24
51.00%
52.33%
1993
19.06
19.26
18.62
19.10
8.25
8.38
53.30%
52.43%
1994
20.00
19.38
19.56
19.18
8.63
8.51
52.79%
52.54%
1995
20.16
19.49
19.85
19.26
8.72
8.65
52.98%
54.80%
1996
19.44
19.61
19.45
19.34
8.75
8.79
56.71%
57.00%
1997
19.80
19.73
19.32
19.42
8.88
8.93
60.54%
59.14%
1998
19.72
19.85
19.41
19.50
8.69
8.65
61.45%
61.22%
1999
19.92
19.97
19.78
19.58
8.32
8.39
63.32%
63.22%
2000
19.60
20.09
19.25
19.66
8.17
8.13
64.67%
65.15%
2001
19.93
20.22
19.62
19.74
7.91
7.87
66.85%
67.01%
2002
20.22
20.34
19.69
19.82
7.65
7.63
70.45%
68.79%
2003
20.35
20.46
19.92
19.90
7.38
7.39
70.60%
69.49%
2004
21.06
20.59
20.52
19.99
7.09
7.16
70.88%
70.19%
2005
20.75
20.71
20.05
20.07
6.95
6.94
72.34%
70.87%
2006
20.33
20.84
19.96
20.15
6.74
6.73
71.22%
71.54%
2007
21.24
20.97
20.41
20.23
6.59
6.58
72.28%
72.20%
2008
21.01
20.82
20.34
20.32
6.41
6.44
73.56%
72.84%
2009
20.87
20.67
20.61
20.40
6.30
6.30
75.21%
73.48%
2010
20.99
20.52
20.55
20.22
6.14
6.17
75.10%
74.10%
2011
19.56
20.37
19.19
20.04
6.04
6.04
74.78%
74.71%
2012
20.40
20.23
19.62
19.86
5.93
5.91
75.93%
75.31%
2013
19.55
20.08
19.29
19.69
5.74
5.78
76.30%
75.89%
2014
20.34
19.94
19.96
19.51
5.70
5.66
76.57%
76.47%
2015
19.99
19.79
19.51
19.34
5.52
5.53
78.11%
77.03%
2016
19.55
19.65
19.27
19.17
5.43
5.42
77.90%
76.58%
2017
19.63
19.51
18.93
19.00
5.37
5.30
-
76.12%
2018
19.45
19.37
18.87
18.83
5.20
5.19
-
75.65%
2019
19.03
19.23
18.71
18.66
5.10
5.08
-
75.18%
2020
17.83
19.10
17.44
18.49
4.96
4.97
-
74.70%
2021
18.99
18.96
18.25
18.33
4.86
4.86
-
74.21%
2022
-
-
-
-
4.69
4.76
-
73.71%
Rate of New Cases and Deaths per 100,000: The rate of new cases of non-Hodgkin lymphoma was 18.6 per 100,000 men and women per year. The death rate was 5.0 per 100,000 men and women per year. These rates are age-adjusted and based on 2017–2021 cases and 2018–2022 deaths.
Lifetime Risk of Developing Cancer: Approximately 2.1 percent of men and women will be diagnosed with non-Hodgkin lymphoma at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID.
Prevalence of This Cancer: In 2021, there were an estimated 808,413 people living with non-Hodgkin lymphoma in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Non-Hodgkin Lymphoma?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
5-Year Relative Survival
74.3%
Based on data from SEER 22 (Excluding IL/MA) 2014–2020. Gray figures represent those who have died from non-Hodgkin lymphoma. Green figures represent those who have survived 5 years or more.
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. The earlier non-Hodgkin lymphoma is caught, the better chance a person has of surviving five years after being diagnosed. For non-Hodgkin lymphoma, 21.8% are diagnosed at stage I. The 5-year relative survival for stage I non-Hodgkin lymphoma is 87.0%.
Percent of Cases & 5-Year Relative Survival by Stage at Diagnosis: Non-Hodgkin Lymphoma
Stage
Percent of Cases
5-Year Relative Survival
Stage I Confined to Single Region
22%
87.0%
Stage II Involving Mulitple Regions
15%
78.9%
Stage III Spread to Both Sides of Diaphragm
18%
73.6%
Stage IV Diffuse or Disseminated Involvement
36%
64.2%
Unknown Unstaged
9%
71.6%
Percent of Cases by Stage
Stage I (22%) Confined to Single Region
Stage II (15%) Involving Mulitple Regions
Stage III (18%) Spread to Both Sides of Diaphragm
Stage IV (36%) Diffuse or Disseminated Involvement
Unknown (9%) Unstaged
5-Year Relative Survival
SEER 17 2014–2020, All Races, Both Sexes by Ann Arbor Stage. Statistics by stage only include cases coded as Lymhpoma or Lymphoma-CLL/SLL in EOD 2018 schema definitions.
Compared to other cancers, non-Hodgkin lymphoma is fairly common.
Rank
Common Types of Cancer
Estimated New Cases 2024
Estimated Deaths 2024
1.
Breast Cancer (Female)
310,720
42,250
2.
Prostate Cancer
299,010
35,250
3.
Lung and Bronchus Cancer
234,580
125,070
4.
Colorectal Cancer
152,810
53,010
5.
Melanoma of the Skin
100,640
8,290
6.
Bladder Cancer
83,190
16,840
7.
Kidney and Renal Pelvis Cancer
81,610
14,390
8.
Non-Hodgkin Lymphoma
80,620
20,140
9.
Uterine Cancer
67,880
13,250
10.
Pancreatic Cancer
66,440
51,750
Non-Hodgkin lymphoma represents 4.0% of all new cancer cases in the U.S.
4.0%
In 2024, it is estimated that there will be 80,620 new cases of non-Hodgkin lymphoma and an estimated 20,140 people will die of this disease.
Who Gets This Cancer?
Non-Hodgkin lymphoma is more common in men than women, and among non-Hispanic Whites. The rate of new cases of non-Hodgkin lymphoma was 18.6 per 100,000 men and women per year based on 2017–2021 cases, age-adjusted.
Rate of New Cases per 100,000 Persons by Race/Ethnicity & Sex: Non-Hodgkin Lymphoma
Males
All Races
22.5
Hispanic
20.0
Non-Hispanic American Indian/Alaska Native
17.4
Non-Hispanic Asian/Pacific Islander
16.1
Non-Hispanic Black
17.1
Non-Hispanic White
24.2
Females
All Races
15.5
Hispanic
15.3
Non-Hispanic American Indian/Alaska Native
12.0
Non-Hispanic Asian/Pacific Islander
11.2
Non-Hispanic Black
12.0
Non-Hispanic White
16.5
All Races
Hispanic
Non-Hispanic American Indian/ Alaska Native
Non-Hispanic Asian / Pacific Islander
Non-Hispanic Black
Non-Hispanic White
SEER 22 2017–2021, Age-Adjusted
Percent of New Cases by Age Group: Non-Hodgkin Lymphoma
Age Range
Percent of New Cases
<20
1.5%
20–34
3.6%
35–44
4.8%
45–54
10.1%
55–64
20.8%
65–74
28.1%
75–84
22.0%
>84
9.0%
Non-Hodgkin lymphoma is most frequently diagnosed among people aged 65–74.
Median Age At Diagnosis
68
SEER 22 2017–2021, All Races, Both Sexes
Who Dies From This Cancer?
Non-Hodgkin lymphoma is the eighth leading cause of cancer death in the United States. The death rate was 5.0 per 100,000 men and women per year based on 2018–2022 deaths, age-adjusted.
Death Rate per 100,000 Persons by Race/Ethnicity & Sex: Non-Hodgkin Lymphoma
Males
All Races
6.5
Hispanic
5.4
Non-Hispanic American Indian/Alaska Native
6.1
Non-Hispanic Asian/Pacific Islander
4.6
Non-Hispanic Black
4.9
Non-Hispanic White
6.9
Females
All Races
3.7
Hispanic
3.5
Non-Hispanic American Indian/Alaska Native
3.4
Non-Hispanic Asian/Pacific Islander
2.7
Non-Hispanic Black
2.8
Non-Hispanic White
3.9
All Races
Hispanic
Non-Hispanic American Indian/ Alaska Native
Non-Hispanic Asian / Pacific Islander
Non-Hispanic Black
Non-Hispanic White
U.S. 2018–2022, Age-Adjusted
Percent of Deaths by Age Group: Non-Hodgkin Lymphoma
Age Range
Percent of Deaths
<20
0.2%
20–34
1.0%
35–44
1.6%
45–54
4.0%
55–64
12.5%
65–74
25.1%
75–84
32.7%
>84
22.9%
The percent of non-Hodgkin lymphoma deaths is highest among people aged 75–84.
Median Age At Death
76
U.S. 2018–2022, All Races, Both Sexes
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new non-Hodgkin lymphoma cases have been falling on average 0.7% each year over 2012–2021. Age-adjusted death rates have been falling on average 2.1% each year over 2013–2022. 5-year relative survival trends are shown below.
New Cases, Deaths and 5-Year Relative Survival
Rate of New Cases
Death Rate
New cases come from SEER 8. Deaths come from U.S. Mortality. All Races, Both Sexes. Rates are Age-Adjusted. Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software. The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
5-Year Relative Survival
SEER 8 5-Year Relative Survival Percent from 1975–2016, All Races, Both Sexes. Modeled trend lines were calculated from the underlying rates using the Joinpoint Survival Model Software.
With SEER*Explorer, you can...
Create custom graphs and tables
Download data and images
Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by sex, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.
Figure: This picture shows lymph nodes above and below the diaphragm. It also shows the lymph vessels, tonsils, thymus, and spleen.
Figure: Lymph Nodes Above and Below the Diaphragm
Figure: This picture shows lymph nodes above and below the diaphragm. It also shows the lymph vessels, tonsils, thymus, and spleen.
Lymphoma is cancer that begins in cells of the lymph system. The lymph system is part of the immune system, which helps the body fight infection and disease. Because lymph tissue is found all through the body, lymphoma can begin almost anywhere.
The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). These can occur in both children and adults.
There are many different types of NHL that form from different types of white blood cells (B-cells, T-cells, NK cells). Most types of NHL form from B-cells. NHL may be indolent (slow-growing) or aggressive (fast-growing). The most common types of NHL in adults are diffuse large B-cell lymphoma, which is usually aggressive, and follicular lymphoma, which is usually indolent.
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
Suggested Citation
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2024 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.
An official website of the United States government
Stage I (22%)
Stage II (15%)
Stage III (18%)
Stage IV (36%)
Unknown (9%)
